#2512284
géardháileog thagartha (ARfD) a leagan síos, i gcás inarb ábhartha, do dhaoine;
establish, where relevant, an acute reference dose (ARfD) for humans;
Scag na torthaí
Bailiúcháin
12 toradh in 12 doiciméad
#2112946
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú mar gheall ar phróifíl ghéarthocsaineachta íseal na substainte.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary due to the low acute toxicity profile of the substance.
#2122445
Bhunaigh sé géardháileog thagartha ghrúpa ina bhfuil 1 μg/kg de mheáchan coirp (b.w.) agus iontógáil laethúil infhulaingthe ghrúpa ina bhfuil 0,6 μg/kg b.w. in aghaidh an lae.
It established a group acute reference dose of 1 μg/kg body weight (b.w.) and a group tolerable daily intake of 0,6 μg/kg b.w. per day.
#2139645
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú ar bhonn phróifíl ghéarthocsaineachta íseal na substainte gníomhaí.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary on the basis of the low acute toxicity profile of the active substance.
#2144869
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú mar gheall ar phróifíl ghéarthocsaineachta íseal na substainte.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary due to the low acute toxicity profile of the substance.
#2480919
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú ar bhonn phróifíl ghéarthocsaineachta íseal na substainte gníomhaí.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary on the basis of the low acute toxicity profile of the active substance.
#2712683
Mhol an tÚdarás, ar bhonn na staidéar ar néarthocsaineacht fhorbarthach, gur cheart iontógáil laethúil inghlactha níos ísle (ADI) agus géardháileog thagartha (ARfD) níos ísle a leagan síos.
The Authority proposed, based on the developmental neurotoxicity studies, that a lower acceptable daily intake (ADI) and acute reference dose (ARfD) should be established.
#516112
(c) tá an iontógáil laethúil inghlactha a bhaineann léi, a géardháileog thagartha, nó a leibhéal inghlactha risíochta i gcás oibreoirí, de réir mar is iomchuí, níos ísle go mór ná an iontógáil laethúil inghlactha, an ghéardháileog thagartha nó an leibhéal inghlactha risíochta i gcás oibreoirí a bhaineann le formhór na substaintí gníomhacha maidir leis an gcineál céanna táirge agus maidir leis an gcás céanna úsáide;
(c) its acceptable daily intake, acute reference dose or acceptable operator exposure level, as appropriate, is significantly lower than those of the majority of approved active substances for the same product-type and use scenario;
#2122847
Shocraigh an tÚdarás géardháileog thagartha ghrúpa (“ARfD”) arb é atá inti 0,016 μg/kg den mheáchan choirp (“b.w.”) arna sloinneadh mar shuim an (-)-hióisciaimín agus an (-)-scópolaimín, ag glacadh leis go bhfuil neart coibhéasach ann.
The Authority established a group acute reference dose (‘ARfD’) of 0.016 μg/kg per body weight (‘b.w.’) expressed as the sum of (-)-hyoscyamine and (-)-scopolamine, assuming equivalent potency.
#2506633
I gcás meatocsaifeinisíde, i gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí sin a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (“an tÚdarás”) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena ndeimhnítear an iontógáil laethúil inghlactha (ILI) atá ann cheana agus lena mbunaítear géardháileog thagartha níos ísle (ARfD).
For methoxyfenozide, in the context of the procedure for the renewal of the approval of that active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, confirming the existing acceptable daily intake (ADI) and establishing a lower acute reference dose (ARfD).
#3206736
I gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí sin a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (‘an tÚdarás’) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena mbunaítear iontógáil laethúil inghlactha (ILI) níos ísle agus géardháileog thagartha níos ísle (ARfD).
In the context of the procedure for the renewal of the approval of that active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, establishing a lower acceptable daily intake (ADI) and a lower acute reference dose (ARfD).
#3211004
I gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí iondocsacarb a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (‘an tÚdarás’) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena mbunaítear iontógáil laethúil inghlactha (‘ADI’) níos ísle agus géardháileog thagartha níos ísle (ARfD).
In the context of the procedure for the renewal of the approval of indoxacarb in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, establishing a lower acceptable daily intake (‘ADI’) and a lower acute reference dose (‘ARfD’).